ECZEMA

This study tests whether lebrikizumab, an injectable biologic, can improve skin symptoms in adults and adolescents (aged 12 and older) with moderate-to-severe atopic dermatitis, also known as eczema. Participants receive lebrikizumab for 24 weeks, and doctors measure changes in e…

This study tested two creams for mild to moderate eczema in 40 children aged 1-12. One cream was a steroid (fluticasone), the other a non-steroid (crisaborole). Both were applied twice daily for 6 weeks, then twice weekly for 12 weeks if the skin improved a lot. Both treatments w…

This study tested whether a moisturizer containing postbiotic Saccharomyces and Lactobacillus can reduce the risk of eczema returning in children aged 0-6 years who are in remission. 98 children used either the special emollient or a standard one for 12 weeks. The goal was to see…

This study compared an online, team-based care model to standard in-person care for managing atopic dermatitis (eczema). 300 patients were randomly assigned to either online or in-person care for 12 months. The goal was to see if the online approach could match in-person care in …

This study tested a new drug, camoteskimab, in 62 adults with moderate to severe eczema (atopic dermatitis). Participants received either the drug or a placebo for 16 weeks, followed by an open-label extension where everyone could get the drug. The main goal was to see if camotes…

This study tests a moisturizing lotion made with Edelweiss extract, macadamia oil, and shea butter in 15 adults with mild-to-moderate eczema. Over 4 weeks, doctors will check skin redness, dryness, and severity, and participants will report any side effects. The goal is to see if…

This study tests whether a daily supplement called NPQ Plus can improve skin health, antioxidant status, fatigue, and well-being in healthy adults with minor skin concerns like dryness or itchiness. The supplement contains polyphenols, NMN, PQQ, CoQ10, and minerals. Participants …

This study tested an experimental drug, EVO301, in 71 adults with moderate-to-severe atopic dermatitis (eczema). The goal was to see if it safely reduces skin redness, thickness, and itch. Participants received either EVO301 or a placebo, and doctors measured changes in skin seve…

This study looked at a specific immune pathway (PGE2/IL22/IL17) in people with eczema to see if it plays a role in the disease. Researchers collected skin and blood samples from 38 participants, including those with eczema, psoriasis, and healthy volunteers. The goal was to ident…

This study looked at how the eczema drug dupilumab (Dupixent) affects immune cells and genes in the skin. Seventeen adults with moderate-to-severe eczema took the drug, and researchers measured changes in skin samples over 12 weeks. The goal was to understand the biological effec…